GlobeImmune Tries Again On IPO

Louisville, Colorado-based GlobeImmune, which it developing biopharmaceuticals for treating treating cancer and infectious diseases, has re-filed for an IPO, saying Monday that it is looking to raised up to $35.0M on the NASDAQ Global Market as GBIM. The IPO is being underwritten by a single undewriter, Aegis Capital Corp. GlobeImmune, which is venture backed by Celgene, HealthCare Ventures, Morgenthaler Partners, Wexford-Kappa Investors, Sequel Ventures, Lilly Ventures, and Medica Venture Partners, had filed for an IPO in 2012, but ended up delaying its IPO on the eve of the offering. The company eventually withdrew its IPO in October of last year.